Skip to content

KIOS Mobile App Evaluation

Evaluation of KIOS in a 12-week Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06212557
Enrollment
116
Registered
2024-01-19
Start date
2024-05-02
Completion date
2025-12-29
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Keywords

Digital health therapeutic, Behavioral intervention strategies, Clinic-based counseling

Brief summary

Evaluation of a mobile medical app (KIOS) vs. treatment as usual for the treatment of opioid use disorder (OUD).

Detailed description

The study is a parallel intervention examining the KIOS app, a digital health therapeutic intended to help individuals in recovery from opioid use disorder better self-manage their condition. KIOS will offer individualized, evidence-based behavioral intervention strategies responsive to the patients' current clinical status outside the setting of the doctor's office or treatment facility. KIOS makes it possible to process patient-entered data and provide responsive behavioral advice to patients specific to their condition in real time. KIOS gives patients 24/7 access to behavioral intervention strategies that can augment and improve response to routine clinic-based counseling interventions.

Interventions

DEVICEKIOS App

KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)

BEHAVIORALKIOS App education

Educational tools provided to participants with opioid use disorder

BEHAVIORALTreatment as usual

Behavioral counseling in clinic

Sponsors

The University of Texas Health Science Center at San Antonio
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Biomedical Development Corporation
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Masking description

Randomization will be stratified by two characteristics: (1) history of MOUD and (2) stimulant use in past one month. Allocation to treatment groups will be randomly assigned by 1:1 allotment to either KIOS + TAU (treatment as usual) or KIOS sham + TAU with strata. Study staff will be blind to the condition to which the participant is assigned.

Intervention model description

Randomized controlled 2 arm trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Male or female outpatients 18 years of age or older 2. Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. 3. DSM-5 (Diagnostic and Statistical Manual of Mental Disorders fifth edition) criteria for opioid use disorder 4. Ability to access KIOS via smartphone or tablet 5. Recently (less than 6 months) enrolled in and currently participating in MOUD at a clinic in Texas

Exclusion criteria

1. Unwilling or unable to comply with study requirements 2. Psychiatric or medical disorder interfering with ability to use the app 3. Incarceration

Design outcomes

Primary

MeasureTime frameDescription
Retention in treatmentBaseline to 13 weeksMeasured by the number of days from the start of the 13-week intervention until the participant either leaves the trial, or completes the trial

Secondary

MeasureTime frameDescription
Measure of opioid use reduction60 days to 13 weeksDefined as abstaining from opioids during the last week and for at least 2 of the previous 3 weeks of the third month of MOUD treatment
Percentage of Opioid Abstinent DaysBaseline to 13 weeksTotal abstinence, measured by urinalysis confirmed self-report of opioid use during the 13-week intervention
Completion of treatmentBaseline to 13 weeksNumber of subjects that completed their participation in the study
Patient Health Questionnaire-9 (PHQ-9)Baseline and 13 weeksA 9 item questionnaire scored from 0 (Not at all) to 4 (Nearly every day) with a potential score of 0-36 with a lower score indicating better health and emotional well-being.
Treatment Effectiveness Assessment TEA)Baseline and 13 weeksThe TEA asks the participant to express the extent of changes for the better from your involvement in the program to this point (or how things are if it's your first TEA or baseline) in four areas: substance use, health, lifestyle, and community. For each area, think about how things have become better and circle the results on the scale below: the more you have improved, the higher the number -from 1 (not better at all) to 10 (very much better). Possible scores are between 1 and 40 with a lower score indicating a worse outcome.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJennifer Potter, PhD, MPH

The University of Texas Health Science Center at San Antonio

PRINCIPAL_INVESTIGATORElise Marino, PhD

The University of Texas Health Science Center at San Antonio

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026